⌘K

Home/Filings/4/0002050422-26-000003

4//SEC Filing

Bachrodt Amy 4

Accession 0002050422-26-000003

CIK 0001842295other

View on SEC.gov Company Profile

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 4:30 PM ET

Size

15.0 KB

Accession

0002050422-26-000003

Insider Transaction Report

Form 4

Period: 2026-01-02

Maze Therapeutics, Inc.MAZE

SVP, Finance

Transactions

Exercise/Conversion
Common Stock
2026-01-02$10.42/sh+204$2,126→ 13,169 total
Exercise/Conversion
Common Stock
2026-01-02$10.42/sh+4,796$49,974→ 17,965 total
Sale
Common Stock
2026-01-02$38.70/sh−2,405$93,072→ 15,560 total
Sale
Common Stock
2026-01-02$39.57/sh−2,595$102,681→ 12,965 total
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−204→ 2,377 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (204 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−4,796→ 2,983 total
Exercise: $10.42Exp: 2031-03-03→ Common Stock (4,796 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.99 per share, inclusive.
[F4]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on November 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
[F5]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 1, 2025.

Documents

1 file

4
form4-01062026_090124.xmlPrimary

Issuer

Maze Therapeutics, Inc.

CIK 0001842295

Entity typeother

Related Parties

1

filerCIK 0002050422

Filing Metadata

Form type: 4
Filed: Jan 5, 7:00 PM ET
Accepted: Jan 6, 4:30 PM ET
Size: 15.0 KB

View on SEC.gov